Correction Notice: Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma

Библиографические подробности
Формат:	Статья
Язык:	English
Опубликовано:	Wiley 2023-03-01
Серии:	HemaSphere
Online-ссылка:	http://journals.lww.com/10.1097/HS9.0000000000000856

Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma
по: Pieter Sonneveld, и др.
Опубликовано: (2022-10-01)

Efficiency of pomalidomide therapy in patients with multiple myeloma refractory to lenalidomide
по: I. G. Rekhtina, и др.
Опубликовано: (2019-04-01)

Efficacy of Carfilzomib, Lenalidomide, and Dexamethasone for Extramedullary Intracranial Localization of Multiple Myeloma
по: Giuseppe Mele, и др.
Опубликовано: (2018-01-01)

Planned withdrawal of dexamethasone after pomalidomide low-dose dexamethasone induction for lenalidomide-refractory multiple myeloma (ALLG MM14)
по: Anna Kalff, и др.
Опубликовано: (2021-09-01)

Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma
по: Dominik Dytfeld, и др.
Опубликовано: (2014-09-01)

Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma
по: Andrew J. Yee, и др.
Опубликовано: (2025-03-01)

Real‐world use of carfilzomib combined with lenalidomide and dexamethasone in patients with multiple myeloma in Europe and Israel
по: Xavier Leleu, и др.
Опубликовано: (2023-02-01)

P48 CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED REFRACTORY MULTIPLE MYELOMA: A PROSPECTIVE REAL-LIFE EXPERIENCE OF THE REGIONAL TUSCAN MYELOMA NETWORK (RTM)
по: I. Attucci, и др.
Опубликовано: (2023-05-01)

Phase II trial of elotuzumab with pomalidomide and dexamethasone for daratumumab-refractory multiple myeloma
по: Ricardo D. Parrondo, и др.
Опубликовано: (2024-09-01)

Economic Evaluation of Adding Daratumumab to Carfilzomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma
по: Yi L, и др.
Опубликовано: (2024-11-01)

P901: POMALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE IN LENALIDOMIDE–PRETREATED MULTIPLE MYELOMA: A SUBANALYSIS OF OPTIMISMM BY FRAILTY
по: A. Oriol, и др.
Опубликовано: (2022-06-01)

MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma
по: Manisha Bhutani, и др.
Опубликовано: (2025-02-01)

Case of Stroke from Cerebral Vasculitis following Carfilzomib, Lenalidomide, and Dexamethasone Therapy in a Patient with Relapsing Multiple Myeloma
по: Deborah Osafehinti, и др.
Опубликовано: (2019-01-01)

Isatuximab-pomalidomide-dexamethasone <i>versus</i> pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis
по: Paul G. Richardson, и др.
Опубликовано: (2024-02-01)

Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX
по: Meletios A. Dimopoulos, и др.
Опубликовано: (2018-12-01)

Superior outcomes and high-risk features with carfilzomib, lenalidomide, and dexamethasone combination therapy for patients with relapsed and refractory multiple myeloma: Results of the multicenter KMMWP2201 study
по: Ji Hyun Lee, и др.
Опубликовано: (2024-06-01)

The Real-World Outcomes of Relapsed/Refractory Multiple Myeloma Treated with Elotuzumab, Pomalidomide, and Dexamethasone
по: Hitomi Nakayama, и др.
Опубликовано: (2024-09-01)

Isatuximab, pomalidomide and dexamethasone in the treatment of relapsed/refractory multiple myeloma in real clinical practice
по: Vadim V. Ptushkin, и др.
Опубликовано: (2024-12-01)

P937: CARFILZOMIB, LENALIDOMIDE PLUS DEXAMETHASONE (KRD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: UPDATE ANALYSIS OF REAL-LIFE EXPERIENCE OF GEMMAC GROUP.
по: Antonio Garcia-Guiñon, и др.
Опубликовано: (2023-08-01)

Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab (“Pom‐PAD‐Dara”) in relapsed/refractory multiple myeloma
по: Xiang Zhou, и др.
Опубликовано: (2020-08-01)

P907: CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB (KDD) VS CARFILZOMIB AND DEXAMETHASONE (KD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): FRAILTY SUBGROUP ANALYSIS OF THE CANDOR STUDY
по: H. Quach, и др.
Опубликовано: (2022-06-01)

S175: ATLAS: A PHASE 3 RANDOMIZED TRIAL OF CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE VERSUS LENALIDOMIDE ALONE AFTER STEM-CELL TRANSPLANT FOR MULTIPLE MYELOMA
по: D. Dytfeld, и др.
Опубликовано: (2022-06-01)

Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant
по: Benjamin A. Derman, и др.
Опубликовано: (2024-05-01)

Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone
по: Meletios A. Dimopoulos, и др.
Опубликовано: (2015-10-01)

Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma
по: Gooding, S, и др.
Опубликовано: (2020)

PB2164: EFFICACY AND SAFETY EVALUATION OF IXAZOMIB, POMALIDOMIDE, AND DEXAMETHASONE IN THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA
по: Wen LI, и др.
Опубликовано: (2023-08-01)

Tumor Lysis Syndrome with Venetoclax/Carfilzomib/Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Case Report
по: Reilly Fankhauser, и др.
Опубликовано: (2024-11-01)

Venetoclax in combination with carfilzomib, doxorubicin and dexamethasone restores responsiveness in an otherwise treatment-refractory multiple myeloma patient
по: Sarolta Bojtine Kovacs, и др.
Опубликовано: (2020-03-01)

Phase I/Ib study of carfilzomib and panobinostat with or without dexamethasone in patients with relapsed/refractory multiple myeloma
по: Elisabet E. Manasanch, и др.
Опубликовано: (2020-05-01)

Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis
по: Marcelo Capra, и др.
Опубликовано: (2021-10-01)

The role of pomalidomide in treatment of relapse and refractory multiple myeloma
по: S. V. Voloshin, и др.
Опубликовано: (2022-01-01)

Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone
по: Efstathios Kastritis, и др.
Опубликовано: (2019-12-01)

PB1986: ADDITION OF CARFILZOMIB AS A THIRD AGENT IN LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA: SWITCHING FROM DOUBLET TO TRIPLET
по: C. Cerchione, и др.
Опубликовано: (2022-06-01)

P893: CARFILZOMIB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE (KRD) AS SALVAGE THERAPY FOR MULTIPLE MYELOMA PATIENTS: ITALIAN, MULTICENTER, RETROSPECTIVE EXPERIENCE OUTSIDE OF CLINICAL TRIALS
по: E. A. Martino, и др.
Опубликовано: (2022-06-01)

Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1
по: María-Victoria Mateos, и др.
Опубликовано: (2017-10-01)

Lenalidomide for relapsed or refractory multiple myeloma
по: S. S. Bessmeltsev1, и др.
Опубликовано: (2014-07-01)

Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis
по: Fredrik Schjesvold, и др.
Опубликовано: (2022-03-01)

Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis
по: Fredrik H. Schjesvold, и др.
Опубликовано: (2020-06-01)

P968: ADDITION OF IXAZOMIB TO POMALIDOMIDE AND DEXAMETHASONE IMPROVES PROGRESSION-FREE SURVIVAL FOR MULTIPLE MYELOMA PATIENTS PROGRESSING ON LENALIDOMIDE AS PART OF 1ST LINE THERAPY: ALLIANCE A061202
по: P. Voorhees, и др.
Опубликовано: (2022-06-01)

Isatuximab‐carfilzomib‐dexamethasone immediately after failing of the quadruplet Daratumumab‐bortezomib‐lenalidomide‐dexamethasone (Dara‐VRD): Striking response with no washout in a newly diagnosed multiple myeloma
по: Juan José Gil‐Fernández, и др.
Опубликовано: (2024-01-01)

Correction Notice: Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma

Схожие документы

Схожие документы